Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (391-400 of 427) with videos related to

Pageof 43
Sort By:
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Hemasphere|April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myelomaJan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Nature Medicine|July 1, 2026
Clinical decision support in hematological malignancies using a case-grounded AI agentJulian Zoller, Michael Kalz, Xuewei Wu, et al.
Nature Communications|November 29, 2024
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapyRaphael Lutz, Florian Grünschläger, Malte Simon, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Hemasphere|October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myelomaNiccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple MyelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Blood Cancer Journal|October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myelomaJia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
Pageof 43

Showing results (391-400 of 427) with videos related to

Sort By:
Pageof 43
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Hemasphere|April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myelomaJan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Nature Medicine|July 1, 2026
Clinical decision support in hematological malignancies using a case-grounded AI agentJulian Zoller, Michael Kalz, Xuewei Wu, et al.
Nature Communications|November 29, 2024
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapyRaphael Lutz, Florian Grünschläger, Malte Simon, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Hemasphere|October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myelomaNiccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple MyelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Blood Cancer Journal|October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myelomaJia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
Pageof 43